Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:DBVT NASDAQ:FENC NASDAQ:IMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$2.68-2.5%$3.11$0.40▼$5.48$64.74M0.27104,576 shs65,255 shsDBVTDBV Technologies$9.52+1.3%$9.80$2.20▼$12.78$257.51M-0.3628,039 shs29,657 shsFENCAdherex Technologies$9.01-2.3%$8.63$3.96▼$9.42$257.34M0.5864,112 shs39,330 shsIMRXImmuneering$8.14+15.5%$4.37$1.10▼$9.37$293.07M0.431.04 million shs3.32 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-2.55%-1.11%-9.15%+44.86%+300.36%DBVTDBV Technologies+1.28%+4.50%-0.48%-1.75%+138.00%FENCAdherex Technologies-2.28%+1.69%+9.21%+8.29%+71.95%IMRXImmuneering+15.46%+51.58%+153.58%+315.31%+581.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$2.68-2.5%$3.11$0.40▼$5.48$64.74M0.27104,576 shs65,255 shsDBVTDBV Technologies$9.52+1.3%$9.80$2.20▼$12.78$257.51M-0.3628,039 shs29,657 shsFENCAdherex Technologies$9.01-2.3%$8.63$3.96▼$9.42$257.34M0.5864,112 shs39,330 shsIMRXImmuneering$8.14+15.5%$4.37$1.10▼$9.37$293.07M0.431.04 million shs3.32 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-2.55%-1.11%-9.15%+44.86%+300.36%DBVTDBV Technologies+1.28%+4.50%-0.48%-1.75%+138.00%FENCAdherex Technologies-2.28%+1.69%+9.21%+8.29%+71.95%IMRXImmuneering+15.46%+51.58%+153.58%+315.31%+581.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 0.00N/AN/AN/ADBVTDBV Technologies 2.80Moderate Buy$14.7554.94% UpsideFENCAdherex Technologies 3.00Buy$13.3347.98% UpsideIMRXImmuneering 2.60Moderate Buy$13.0059.71% UpsideCurrent Analyst Ratings BreakdownLatest ABVC, DBVT, FENC, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.008/21/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.008/15/2025FENCAdherex TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $14.008/14/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.006/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$21.006/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K123.70N/AN/A$0.06 per share44.67DBVTDBV Technologies$4.15M62.85N/AN/A$1.42 per share6.70FENCAdherex Technologies$47.54M5.29$0.03 per share285.49($0.21) per share-42.90IMRXImmuneering$320K1,057.44N/AN/A$1.33 per share6.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$4.90M-$0.17N/A∞N/A-963.46%-46.76%-23.02%11/12/2025 (Estimated)DBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)FENCAdherex Technologies-$440K-$0.42N/AN/AN/A-35.05%N/A-23.92%11/6/2025 (Estimated)IMRXImmuneering-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%11/12/2025 (Estimated)Latest ABVC, DBVT, FENC, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FENCAdherex Technologies-$0.06-$0.11-$0.05-$0.11$9.52 million$9.76 million8/13/2025Q2 2025ABVCABVC BioPharmaN/A-$0.13N/A-$0.13N/AN/A8/13/2025Q2 2025IMRXImmuneering-$0.40-$0.40N/A-$0.40N/AN/A7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.420.42DBVTDBV TechnologiesN/A2.452.45FENCAdherex TechnologiesN/A4.854.59IMRXImmuneeringN/A3.703.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%DBVTDBV Technologies71.74%FENCAdherex Technologies55.51%IMRXImmuneering67.65%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma17.10%DBVTDBV Technologies1.44%FENCAdherex Technologies11.76%IMRXImmuneering22.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3023.54 million19.52 millionNot OptionableDBVTDBV Technologies8027.40 million27.00 millionOptionableFENCAdherex Technologies1027.91 million24.63 millionOptionableIMRXImmuneering6041.57 million28.00 millionNot OptionableABVC, DBVT, FENC, and IMRX HeadlinesRecent News About These CompaniesImmuneering to announce updated data from Phase 2a trial of Atebimetinib + mGnPSeptember 10 at 5:52 PM | msn.comImmuneering Corporation to Host Investor Call and Present Updated Data at Upcoming Scientific ConferencesSeptember 10 at 7:31 AM | quiverquant.comQImmuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25September 10 at 7:00 AM | globenewswire.comBrokerages Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.00September 7, 2025 | americanbankingnews.comImmuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 6, 2025 | marketbeat.comPleasing Signs As A Number Of Insiders Buy Immuneering StockSeptember 5, 2025 | finance.yahoo.comImmuneering files to sell 9.18M shares of Class A common stock for holdersSeptember 3, 2025 | msn.comImmuneering (NASDAQ:IMRX) Receives "Buy" Rating from Needham & Company LLCAugust 28, 2025 | marketbeat.comImmuneering Corporation: Ripping On A Questionable CatalystAugust 26, 2025 | seekingalpha.comImmuneering Corporation Closes $25 Million Private Placement to Support Oncology Drug DevelopmentAugust 26, 2025 | quiverquant.comQImmuneering Announces Closing of $25 Million Private PlacementAugust 26, 2025 | globenewswire.comImmuneering Stock Rises 21.7% on Supply Agreement With LLYAugust 26, 2025 | zacks.comImmuneering signs supply deal with Lilly to test atebimetinib plus olomorasibAugust 25, 2025 | msn.comImmuneering stock soars on clinical supply deal with Eli LillyAugust 25, 2025 | za.investing.comImmuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On DipsAugust 25, 2025 | msn.comImmuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with OlomorasibAugust 25, 2025 | globenewswire.comImmuneering prices 6.3M shares at $3.95 in private placementAugust 22, 2025 | msn.comImmuneering Secures $25 Million in Private Placement to Advance Cancer Drug DevelopmentAugust 22, 2025 | msn.comImmuneering Corporation Announces $25 Million Private Placement Financing to Support Development of Innovative Cancer TreatmentsAugust 21, 2025 | quiverquant.comQImmuneering Announces $25 Million Private PlacementAugust 21, 2025 | globenewswire.comImmuneering (NASDAQ:IMRX) Announces Quarterly Earnings Results, Meets ExpectationsAugust 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVC, DBVT, FENC, and IMRX Company DescriptionsABVC BioPharma NASDAQ:ABVC$2.68 -0.07 (-2.55%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$2.68 +0.00 (+0.19%) As of 06:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.DBV Technologies NASDAQ:DBVT$9.52 +0.12 (+1.28%) Closing price 09/10/2025 03:46 PM EasternExtended Trading$9.99 +0.48 (+4.99%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Adherex Technologies NASDAQ:FENC$9.01 -0.21 (-2.28%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$9.10 +0.09 (+0.99%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Immuneering NASDAQ:IMRX$8.14 +1.09 (+15.46%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$8.38 +0.24 (+3.01%) As of 06:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
